Jul 23, 2025 13:26
CUE - Cue Biopharma, Inc.
Day | 1m | 10m | 60m | PreMarket | Market | AfterHours | Gap |
---|---|---|---|---|---|---|---|
0.8 -0.01 (-1.54%) | --- | --- | --- | 0.0 (0.0%) | -0.02 (-1.88%) | --- | 0.0 (0.0%) |
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
Category:
PHARMACEUTICAL PREPARATIONS
Market Period:
AfterHours
Earnings & Ratios
- Basic EPS:
- -0.09
- Diluted EPS:
- -0.09
- Basic P/E:
- -8.7222
- Diluted P/E:
- -8.7222
- RSI(14) 1m:
- 50.0
- VWAP:
- 0.79
- RVol:
- 1.0021
Events
Period | Kind | Movement | Occurred At |
---|---|---|---|
1m | Price increase 1m | 0.8 +0.01 (+1.06%) | Oct 15 10:10 |
Related News
Jun 24, 2025 20:48
Apr 15, 2025 02:23
Apr 15, 2025 02:23
Apr 14, 2025 21:00
Nov 29, 2024 21:30
Nov 25, 2024 13:00
Nov 14, 2024 13:00
Nov 08, 2024 18:30
Sep 27, 2024 03:26